In addition, close to $ 8 billion was spent in Guinea, Liberia and Sierra Leone for the development of Ebola drugs and treatment reported ‘NY Times ‘. The same source revealed that getting a vaccine costs anywhere between $500 million as well as $1 billion. These funds help several drug manufacturers or biotechnology firms and scientists that are working hard to produce vaccines but are deprived of resources to manufacture them or seek an approval. Moreover, with the ‘World Health Organization’ supporting clinical trials of the vaccine in areas including Guinea has acted as a boon for fund raising and has attracted contributions from several private companies and drug makers for new virus vaccine.
In July 2015, health experts from across the global seconded the need for creating a $2 billion Ebola virus vaccine production fund to boost new shots. Commenting on this the Welcome Trust’s director, Jeremy Farrar said "We can no longer sit back and ignore the chronic lack of progress in developing new vaccines, and improving existing ones." Jeremy was of the co – writers responsible for creating the fund. Allied Market Research has added a report titled “Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020.” As per the report the vaccine manufacturing in regions such as Asia – Pacific, LAMEA, Europe and North America would observe tremendous growth.